AveXis, Inc. (NASDAQ:AVXS) had its price objective increased by Royal Bank Of Canada from $92.00 to $97.00 in a report released on Friday morning, Marketbeat reports. They currently have a sector perform rating on the stock.
Other equities research analysts have also recently issued reports about the company. Sanford C. Bernstein assumed coverage on AveXis in a research note on Thursday, July 27th. They issued an outperform rating and a $108.00 price objective for the company. Evercore ISI assumed coverage on AveXis in a research note on Wednesday, August 16th. They issued an outperform rating and a $120.00 price objective for the company. Wells Fargo & Company reaffirmed an outperform rating and issued a $134.00 price objective (up from $89.00) on shares of AveXis in a research note on Tuesday, September 5th. Zacks Investment Research raised AveXis from a sell rating to a hold rating in a research note on Thursday, July 13th. Finally, BMO Capital Markets reaffirmed a buy rating and issued a $123.00 price objective on shares of AveXis in a research note on Friday, August 11th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $108.26.
Shares of AveXis (NASDAQ:AVXS) traded up $1.20 during midday trading on Friday, hitting $96.99. The stock had a trading volume of 388,400 shares, compared to its average volume of 435,648. AveXis has a twelve month low of $44.68 and a twelve month high of $108.27.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same quarter last year, the business earned ($0.87) earnings per share. sell-side analysts predict that AveXis will post -5.55 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://transcriptdaily.com/2017/11/14/avexis-inc-avxs-pt-raised-to-97-00-at-royal-bank-of-canada.html.
In other news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $97.25, for a total transaction of $173,105.00. Following the completion of the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $173,105. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $101.23, for a total value of $1,518,450.00. Following the transaction, the insider now directly owns 1,841,019 shares of the company’s stock, valued at $186,366,353.37. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,340 shares of company stock valued at $3,559,683. Insiders own 18.60% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its position in shares of AveXis by 41.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,871 shares of the company’s stock worth $2,043,000 after acquiring an additional 7,321 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of AveXis by 31.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock valued at $129,419,000 after purchasing an additional 380,396 shares during the last quarter. Tocqueville Asset Management L.P. purchased a new stake in shares of AveXis in the 2nd quarter valued at about $552,000. TimesSquare Capital Management LLC purchased a new stake in shares of AveXis in the 2nd quarter valued at about $6,162,000. Finally, Credit Suisse AG lifted its holdings in shares of AveXis by 36.4% in the 1st quarter. Credit Suisse AG now owns 63,228 shares of the company’s stock valued at $4,807,000 after purchasing an additional 16,876 shares during the last quarter. 94.96% of the stock is owned by institutional investors and hedge funds.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.